Guidelines  ||| S:0 E:11 ||| NNS
for  ||| S:11 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
role  ||| S:19 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
FDG-PET ||| S:27 E:34 ||| NNP
/ ||| S:34 E:35 ||| NNP
CT  ||| S:35 E:38 ||| NNP
in  ||| S:38 E:41 ||| IN
lung  ||| S:41 E:46 ||| NN
cancer  ||| S:46 E:53 ||| NN
management  ||| S:53 E:64 ||| NN
Fluoro-2-deoxy-d-glucose  ||| S:64 E:89 ||| NNP
( ||| S:89 E:90 ||| -LRB-
FDG ||| S:90 E:93 ||| NNP
) ||| S:93 E:94 ||| -RRB-
-positron  ||| S:94 E:104 ||| FW
emission  ||| S:104 E:113 ||| FW
tomography  ||| S:113 E:124 ||| FW
( ||| S:124 E:125 ||| -LRB-
PET ||| S:125 E:128 ||| NNP
)  ||| S:128 E:130 ||| -RRB-
and  ||| S:130 E:134 ||| CC
PET ||| S:134 E:137 ||| NNP
/ ||| S:137 E:138 ||| FW
computed  ||| S:138 E:147 ||| FW
tomography  ||| S:147 E:158 ||| FW
( ||| S:158 E:159 ||| -LRB-
FDG-PET ||| S:159 E:166 ||| NNP
/ ||| S:166 E:167 ||| NNP
CT ||| S:167 E:169 ||| NNP
)  ||| S:169 E:171 ||| -RRB-
is  ||| S:171 E:174 ||| VBZ
regarded  ||| S:174 E:183 ||| VBN
as  ||| S:183 E:186 ||| IN
a  ||| S:186 E:188 ||| DT
standard  ||| S:188 E:197 ||| NN
of  ||| S:197 E:200 ||| IN
care  ||| S:200 E:205 ||| NN
in  ||| S:205 E:208 ||| IN
the  ||| S:208 E:212 ||| DT
management  ||| S:212 E:223 ||| NN
of  ||| S:223 E:226 ||| IN
non-small-cell  ||| S:226 E:241 ||| JJ
lung  ||| S:241 E:246 ||| NN
carcinoma  ||| S:246 E:256 ||| NNS
( ||| S:256 E:257 ||| -LRB-
NSCLC ||| S:257 E:262 ||| NNP
)  ||| S:262 E:264 ||| -RRB-
and  ||| S:264 E:268 ||| CC
is  ||| S:268 E:271 ||| VBZ
a  ||| S:271 E:273 ||| DT
useful  ||| S:273 E:280 ||| JJ
adjunct  ||| S:280 E:288 ||| NN
in  ||| S:288 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
characterization  ||| S:295 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
indeterminate  ||| S:315 E:329 ||| FW
solitary  ||| S:329 E:338 ||| FW
lung  ||| S:338 E:343 ||| FW
nodules  ||| S:343 E:351 ||| FW
( ||| S:351 E:352 ||| -LRB-
SLN ||| S:352 E:355 ||| NNP
) ||| S:355 E:356 ||| -RRB-
,  ||| S:356 E:358 ||| ,
and  ||| S:358 E:362 ||| CC
pre-treatment  ||| S:362 E:376 ||| JJ
staging  ||| S:376 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
NSCLC ||| S:387 E:392 ||| NNP
,  ||| S:392 E:394 ||| ,
notably  ||| S:394 E:402 ||| RB
mediastinal  ||| S:402 E:414 ||| JJ
nodal  ||| S:414 E:420 ||| JJ
staging  ||| S:420 E:428 ||| NN
and  ||| S:428 E:432 ||| CC
detection  ||| S:432 E:442 ||| NN
of  ||| S:442 E:445 ||| IN
remote  ||| S:445 E:452 ||| JJ
metastases ||| S:452 E:462 ||| NN
.  ||| S:462 E:464 ||| .
FDG-PET ||| S:464 E:471 ||| NNP
/ ||| S:471 E:472 ||| NNP
CT  ||| S:472 E:475 ||| NNP
has  ||| S:475 E:479 ||| VBZ
the  ||| S:479 E:483 ||| DT
ability  ||| S:483 E:491 ||| NN
to  ||| S:491 E:494 ||| TO
assess  ||| S:494 E:501 ||| VB
locoregional  ||| S:501 E:514 ||| JJ
lymph  ||| S:514 E:520 ||| NNS
node  ||| S:520 E:525 ||| VBP
spread  ||| S:525 E:532 ||| VBN
more  ||| S:532 E:537 ||| RBR
precisely  ||| S:537 E:547 ||| RB
than  ||| S:547 E:552 ||| IN
CT ||| S:552 E:554 ||| NNP
,  ||| S:554 E:556 ||| ,
to  ||| S:556 E:559 ||| TO
detect  ||| S:559 E:566 ||| VB
metastatic  ||| S:566 E:577 ||| JJ
lesions  ||| S:577 E:585 ||| NNS
that  ||| S:585 E:590 ||| WDT
would  ||| S:590 E:596 ||| MD
have  ||| S:596 E:601 ||| VB
been  ||| S:601 E:606 ||| VBN
missed  ||| S:606 E:613 ||| VBN
on  ||| S:613 E:616 ||| IN
conventional  ||| S:616 E:629 ||| JJ
imaging  ||| S:629 E:637 ||| NN
or  ||| S:637 E:640 ||| CC
are  ||| S:640 E:644 ||| VBP
located  ||| S:644 E:652 ||| VBN
in  ||| S:652 E:655 ||| IN
difficult  ||| S:655 E:665 ||| JJ
areas ||| S:665 E:670 ||| NNS
,  ||| S:670 E:672 ||| ,
and  ||| S:672 E:676 ||| CC
to  ||| S:676 E:679 ||| TO
help  ||| S:679 E:684 ||| VB
in  ||| S:684 E:687 ||| IN
the  ||| S:687 E:691 ||| DT
differentiation  ||| S:691 E:707 ||| NN
of  ||| S:707 E:710 ||| IN
lesions  ||| S:710 E:718 ||| NNS
that  ||| S:718 E:723 ||| WDT
are  ||| S:723 E:727 ||| VBP
equivocal  ||| S:727 E:737 ||| VBN
after  ||| S:737 E:743 ||| IN
conventional  ||| S:743 E:756 ||| JJ
imaging ||| S:756 E:763 ||| NN
.  ||| S:763 E:765 ||| .
Increasingly  ||| S:765 E:778 ||| RB
FDG-PET ||| S:778 E:785 ||| JJ
/ ||| S:785 E:786 ||| NNP
CT  ||| S:786 E:789 ||| NNP
is  ||| S:789 E:792 ||| VBZ
employed  ||| S:792 E:801 ||| VBN
in  ||| S:801 E:804 ||| IN
radiotherapy  ||| S:804 E:817 ||| JJ
planning ||| S:817 E:825 ||| NN
,  ||| S:825 E:827 ||| ,
prediction  ||| S:827 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
prognosis  ||| S:841 E:851 ||| NN
in  ||| S:851 E:854 ||| IN
terms  ||| S:854 E:860 ||| NNS
of  ||| S:860 E:863 ||| IN
tumor  ||| S:863 E:869 ||| NN
response  ||| S:869 E:878 ||| NN
to  ||| S:878 E:881 ||| TO
neo-adjuvant ||| S:881 E:893 ||| JJ
,  ||| S:893 E:895 ||| ,
radiation  ||| S:895 E:905 ||| NN
and  ||| S:905 E:909 ||| CC
chemotherapy  ||| S:909 E:922 ||| JJ
treatment ||| S:922 E:931 ||| NN
.  ||| S:931 E:933 ||| .
Evidence  ||| S:933 E:942 ||| NN
is  ||| S:942 E:945 ||| VBZ
accumulating  ||| S:945 E:958 ||| VBG
of  ||| S:958 E:961 ||| IN
usefulness  ||| S:961 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
PET ||| S:975 E:978 ||| NNP
/ ||| S:978 E:979 ||| NNP
CT  ||| S:979 E:982 ||| NNP
in  ||| S:982 E:985 ||| IN
small  ||| S:985 E:991 ||| JJ
cell  ||| S:991 E:996 ||| NN
lung  ||| S:996 E:1001 ||| NN
cancer ||| S:1001 E:1007 ||| NN
.  ||| S:1007 E:1009 ||| .
